NeurogesX, Inc. Completes Enrollment In Pivotal Phase 3 Postherpetic Neuralgia Trial
SAN CARLOS, Calif.--(BUSINESS WIRE)--June 13, 2006--NeurogesX, Inc., a privately held specialty pharmaceutical company, today announced that it has completed enrollment in its 400-patient Phase 3 trial of its investigational drug Transacin(TM) (NGX-4010) in patients suffering from postherpetic neuralgia (PHN). Transacin is NeurogesX's novel high-concentration trans-capsaicin dermal patch. The randomized, double blind, controlled study is being conducted at more than 50 U.S. clinical sites. The company expects final data from this study to be available in the fourth quarter of this year.